Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Alpha Teknova, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Second Quarter 2023 Financial Results Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year HOLLISTER, Calif., August 10, 2023 – Alpha Teknova, Inc. , a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2023. “Today we reported strong operating results for the second quarter of 2023, increasing revenue sequentially by 26%, despite a challenging market environment..." |
|
| 07/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/15/2023 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Fourth Quarter and Full Year 2022 Financial Results Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million HOLLISTER, Calif., March 15, 2023 – Alpha Teknova, Inc. , a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and the full year ended December 31, 2022. “We achieved our operational objectives in 2022, positioning the company for significant and sustainable long-term growth,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. “Despi..." |
|
| 11/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Third Quarter 2022 Financial Results Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability HOLLISTER, Calif., November 9, 2022 – Alpha Teknova, Inc. , a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2022. “Teknova delivered a solid third quarter revenue performance, driven by robust Lab Essentials growth and healthy demand across our broad customer base,” said Stephen Gunstream, President and CEO of Teknova. “Most recently, we ent..." |
|
| 08/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Second Quarter 2022 Financial Results Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 million HOLLISTER, Calif., August 10, 2022 – Alpha Teknova, Inc. , a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2022. “We were pleased with our second quarter revenue growth and the excellent progress on the build-out of our new manufacturing facility,” said Stephen Gunstream, President and CEO of Teknova. “While we continue to see healthy ..." |
|
| 06/03/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 03/15/2022 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Offer Letter, between Alpha Teknova, Inc. and Ken Gelhaus",
"Teknova Expands Leadership Team with the Appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President, Marketing HOLLISTER, Calif., Nov 10, 2021 - Alpha Teknova, Inc. , a leading manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, today announced the appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President, Marketing. “We're truly excited that Ken and Jennifer have chosen to join our leadership team,” said Stephen Gunstream, CEO of Teknova. “Both of them bring uniquely valuable experience to their roles,” he continued. “Ken knows how to build and lead successful commercial organizations in complex life sciences businesses. That's what we've challen..." |
|
| 11/10/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 06/29/2021 |
8-K
| Quarterly results |
|
|